Related Experiment Video
Updated: Apr 19, 2026
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis
Maxime Beydon1, David Hajage1, Alexis F Guédon2
1Sorbonne Université, Institut pour la Santé et la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe PEPITES, Assistance Publique - Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Paris, France.
Insights
Low-dose aspirin initiation after giant cell arteritis (GCA) diagnosis reduced major adverse cardiovascular events (MACE) risk but increased hemorrhage risk within one year. Benefits persisted at three years, with notable differences in women and diabetic patients.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Pharmacology
Background:
- Giant cell arteritis (GCA) patients have elevated risk for major adverse cardiovascular events (MACE).
- The role of low-dose aspirin in primary prevention for GCA patients remains unclear.
Purpose of the Study:
- To assess the association between low-dose aspirin and MACE risk in primary prevention among incident GCA patients.
- To evaluate the risks of major hemorrhage and the net clinical benefit of low-dose aspirin in GCA.
Main Methods:
- Population-based cohort study using target trial emulation with cloning, censoring, and weighting.
- Included individuals aged 50+ with incident GCA, excluding prior cardiovascular events or antiplatelet/anticoagulant use.
- Compared low-dose aspirin initiation within 14 days of GCA diagnosis versus no initiation.
Main Results:
- Low-dose aspirin was associated with a 1-year reduction in MACE risk (RD -0.54%) and all-cause mortality (RD -0.43%).
- A 1-year increase in major hemorrhage risk (RD 0.51%) was observed with low-dose aspirin.
- MACE events were less frequent at 3 years with low-dose aspirin (RD -1.08%), with no significant difference in hemorrhages.
Conclusions:
- Low-dose aspirin use following GCA diagnosis is linked to reduced MACE at 1 and 3 years, alongside increased hemorrhage risk at 1 year.
- Subgroup analyses indicate potential heterogeneity in response based on sex and diabetes status.
- The findings suggest a complex risk-benefit profile for low-dose aspirin in GCA patients.
Importance:
Patients with giant cell arteritis (GCA) face an increased risk of major adverse cardiovascular events (MACE). The benefit of low-dose aspirin in these patients is unknown.
Objective:
To evaluate the 1-year association of low-dose aspirin with risk of MACE in primary prevention in patients with incident GCA and to evaluate the risk of major hemorrhage and net clinical benefit at predefined time points.
Design, Setting, And Participants:
This population-based cohort study used a target trial emulation framework with a cloning, censoring, and weighting approach within the French National Health Data System. Participants were individuals aged at least 50 years with incident GCA between 2010 and 2022, without previous cardiovascular events or antiplatelet or anticoagulant use at GCA diagnosis. Analysis was conducted from November 2024 to June 2025.
Exposure:
Initiation of low-dose aspirin vs not (control group) within 14 days of GCA diagnosis.
Main Outcomes And Measures:
The main outcome was MACE, a composite end point of ischemic stroke, myocardial infarction, and all-cause mortality. Major hemorrhages were evaluated as secondary outcomes.
Results:
A total of 14 528 individuals (median [IQR] age, 74 [67 to 80] years; 10 396 [72%] female), were included. Low-dose aspirin was initiated in 5220 individuals (36%). At 1 year, MACE risk was lower in the low-dose aspirin group (relative risk [RR], 0.86 [95% CI, 0.75 to 0.96]; risk difference [RD], -0.54% [95% CI, -0.99% to -0.12%]), while major hemorrhage risk was higher (RR, 1.29 [95% CI, 1.05 to 1.53]; RD, 0.51% [95% CI, 0.13% to 0.91%]). All-cause mortality was lower in the low-dose aspirin group at 1 year (RD, -0.43% [95% CI, -0.77% to -0.10%]). At 3 years, MACE events were less frequent in the low-dose aspirin group (RD, -1.08% [95% CI, -1.77% to -0.41%]), with no difference in major hemorrhages. A more pronounced association between low-dose aspirin and lower 1-year MACE was observed in women (RD, -0.78% [95% CI, -1.29% to -0.25%]) and patients with diabetes at GCA diagnosis (RD, -2.23% [95% CI, -3.48% to -1.02%]).
Conclusions And Relevance:
In this retrospective cohort study, low-dose aspirin at GCA diagnosis was associated with lower MACE at 1 and 3 years but higher hemorrhage risk at 1 year. Subgroup analyses suggested heterogeneity according to sex and diabetic status.
Related Concept Videos
01:26Atherosclerosis III: Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Aneurysm III: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:27Peripheral Artery Disease III: Interprofessional Care
01:21Rheumatic Heart Disease III: Medical Management